<DOC>
	<DOCNO>NCT01826487</DOCNO>
	<brief_summary>Dystrophinopathy disease continuum include Duchenne muscular dystrophy , develop boy . It cause mutation gene dystrophin , protein important maintain normal muscle structure function . Loss dystrophin cause muscle fragility lead weakness loss walk ability . A specific type mutation , call nonsense ( premature stop codon ) mutation cause dystrophinopathy approximately 10-15 % boys disease . Ataluren orally deliver , investigational drug potential overcome effect nonsense mutation . The main goal Phase 3 study evaluate effect ataluren walk ability . The effect ataluren physical function , quality life , activity daily live evaluate . This study also provide additional information long-term safety ataluren .</brief_summary>
	<brief_title>Phase 3 Study Ataluren Patients With Nonsense Mutation Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>This study Phase 3 , multicenter , randomize , double-blind , placebo-controlled study determine efficacy safety ataluren 10 , 10 , 20 mg/kg patient nonsense-mutation ( nm ) dystrophinopathy . Patients randomize 1:1 ratio ataluren 10- , 10- , 20-mg/kg dose level placebo . Patients receive study drug TID morning , midday , even . It plan 220 patient enrolled patient undergo 48 week blind treatment prior final analysis . Study assessment perform clinic visit every 8 week . It anticipate open-label extension study available patient ( successfully complete double-blind study ) country ataluren commercially available .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Genetic Diseases , Inborn</mesh_term>
	<mesh_term>Neuromuscular Diseases</mesh_term>
	<mesh_term>Musculoskeletal Diseases</mesh_term>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Genetic Diseases , X-Linked</mesh_term>
	<mesh_term>Muscular Disorders , Atrophic</mesh_term>
	<criteria>Ability provide write informed consent ( parental/guardian consent applicable ) /assent per local requirement . Male sex . Age ≥7 ≤16 year . Phenotypic evidence dystrophinopathy base onset characteristic clinical symptom sign ( eg . proximal muscle weakness , waddle gait , Gowers ' maneuver ) 6 year age , elevate serum creatinine kinase level , ongoing difficulty walk . Documentation presence nonsense point mutation dystrophin gene determine gene sequence laboratory certify College American Pathologists ( CAP ) , Clinical Laboratory Improvement Act/Amendment ( CLIA ) equivalent organization . Documentation blood sample drawn confirmation presence nonsense mutation dystrophin gene . Use systemic corticosteroid ( prednisone , prednisolone , deflazacort ) minimum 6 month immediately prior start study treatment , significant change dosage dose regimen ( relate body weight change ) minimum 3 month immediately prior start study treatment reasonable expectation dosage dose regimen change significantly duration study . Ability walk ≥150 meter unassisted screen 6minute walk test . Patients need protocolspecified threshold % predict 6MWD . Results 2 Baseline 6MWD result must determine valid result Day 2 Baseline 6MWD must within 20 % Day 1 Baseline 6MWD . Baseline 6MWD ( mean valid Day 1 Day 2 value ) must 20 % reduction valid Screening 6MWD . Confirmed screen laboratory value within central laboratory range ( hepatic , renal , serum electrolyte parameter ) Willingness abstain sexual intercourse employ approve method contraception period study drug administration 6week followup period . Willingness ability comply schedule visit , drug administration plan , study procedure , laboratory test , study restriction . Treatment systemic aminoglycoside antibiotic within 3 month prior start study treatment . Initiation systemic corticosteroid therapy within 6 month prior start study treatment . Change systemic corticosteroid therapy ( eg , change type drug , dose modification relate body weight change , schedule modification , interruption , reinitiation ) within 3 month prior start study treatment . Any change ( initiation , change type drug , dose modification , schedule modification , interruption , discontinuation , reinitiation ) prophylaxis/treatment congestive heart failure ( CHF ) within 3 month prior start study treatment . Ongoing use coumarinbased anticoagulant ( eg . warfarin ) , phenytoin , tolbutamide , paclitaxel . Prior therapy ataluren . Known hypersensitivity ingredient excipients study drug Exposure another investigational drug within 3 month prior start study treatment . History major surgical procedure within 6 week prior start study treatment . Ongoing immunosuppressive therapy ( corticosteroid ) . Ongoing participation clinical trial ( except study specifically approve PTC Therapeutics ) . Expectation major surgical procedure ( eg , scoliosis surgery ) 12month treatment period study . Requirement daytime ventilator assistance . Note : Evening ventilator assistance use bilevel positive airway pressure ( BiPAP ) therapy allow . Uncontrolled clinical symptom sign CHF ( American College Cardiology/American Heart Association Stage C Stage D ) . Prior ongoing medical condition ( eg , concomitant illness , psychiatric condition , behavioral disorder , alcoholism , drug abuse ) , medical history , physical finding ( eg . low limb injury may affect 6MWT performance ) , ECG finding , laboratory abnormality , investigator 's opinion , could adversely affect safety subject , make unlikely course treatment followup would complete , could impair assessment study result .</criteria>
	<gender>Male</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>Dystrophinopathy</keyword>
	<keyword>Nonsense mutation</keyword>
	<keyword>Premature stop codon</keyword>
	<keyword>Becker muscular dystrophy</keyword>
	<keyword>DMD/BMD</keyword>
	<keyword>PTC124</keyword>
	<keyword>Ataluren</keyword>
</DOC>